Know Cancer

forgot password

An Open-label, Multi-center Phase I Study to Investigate the Tolerability and Safety of a Continuous Infusion of the Bispecific T-cell Engager MT103 in Patients With Relapsed Non-Hodgkin's Lymphoma (NHL)

Phase 1
18 Years
Not Enrolling
Non-Hodgkin's Lymphoma, Relapsed

Thank you

Trial Information

An Open-label, Multi-center Phase I Study to Investigate the Tolerability and Safety of a Continuous Infusion of the Bispecific T-cell Engager MT103 in Patients With Relapsed Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin's Lymphoma (NHL) represents the 6th most common cancer. Globally, around 165.000
new cases are diagnosed each year, with approx. 90.000 deaths per year. The vast majority of
NHLs are B-cell derived (90%) and express common B-cell antigens such as CD19, CD20 and
CD22. NHL can be divided into indolent (low-grade) and aggressive (high-grade) lymphomas.
Still almost all patients with advanced stage indolent disease will die from their disease.
Therefore, a high medical need exists to develop novel agents that further improve the
survival of NHL patients.

Blinatumomab (MT103) is a bispecific antibody derivative, anti-CD19 x anti-CD3, designed to
link B-cells and T-cells resulting in T-cell activation and a cytotoxic T-cell response
against CD19+ cells. Data of prior phase I studies show evidence of biological activity in
humans. In vitro and ex-vivo data suggest that a longterm presence of the drug in target
tissues may provide antitumour activity.

The study investigates the safety and tolerability of different doses of Blinatumomab
administration in a continuous infusion regimen. MTD will be defined in a classical 3+3 dose
escalation regimen.

Inclusion Criteria:

1. Patients with first or later relapse of histologically (WHO classification)

- follicular lymphoma

- marginal zone lymphoma

- lymphoplasmocytic lymphoma

- mantle cell lymphoma

- diffuse large B-cell lymphoma

- small lymphocytic lymphoma requiring therapy and not eligible for curative

2. Measurable disease (at least one lesion >= 1.5 cm) documented by CT scan

3. Age >= 18 years

4. ECOG performance status <=2

5. Life expectancy of at least 6 months

6. Ability to understand the patient information and informed consent form

7. Signed and dated written informed consent is available

Exclusion Criteria:

1. Any other NHL not listed in inclusion criterion 1

2. Abnormal laboratory values as defined below:

- Peripheral lymphocyte count > 20 x 10x9/l

- Platelet counts ≤ 75,000/µl

- Hb level ≤ 9 g/dL

- Venous pH value out of normal range or oxygen saturation ≤ 90%

3. Known or suspected central nervous system (CNS) involvement by NHL

4. a)History of or current relevant CNS pathology as epilepsy, seizure, paresis,aphasia,
apoplexia, severe brain injuries, cerebellar disease, organic brain syndrome,
psychosis b)Evidence for presence of inflammatory lesions and/or vasculitis on
cerebral MRI

5. Autologous stem cell transplantation within 12 weeks prior to study entry

6. Allogeneic stem cell transplantation

7. Cancer chemotherapy within 4 weeks prior to study entry

8. Radiotherapy within 4 weeks prior to study entry

9. Treatment with rituximab within 4 weeks prior to study entry

10. Prior treatment with alemtuzumab 12 weeks prior to study entry

11. Treatment with any investigational agent within 12 weeks prior to study entry

12. Contraindication for any of the concomitant medications

13. Abnormal renal or hepatic function as defined below:

- AST (SGOT) and/or ALT (SGPT) >= 2 x upper limit of normal (ULN)

- total bilirubin >= 1.5 x ULN

- serum creatinine >= 2 x ULN

- creatinine clearance < 50ml/min

14. Indication of hypercoagulative state as defined below:

-antithrombin activity
15. Presence of human anti-murine antibodies (HAMA) or known hypersensitivity to

16. History of malignancy other than B-cell lymphoma within 5 years prior to study entry,
with the exception of basal cell carcinoma of the skin or carcinoma in situ of the

17. Active infection / not yet recovered from recent infection; known bacteriemia

18. Any concurrent disease or medical condition that is deemed to interfere with the
conduct of the study as judged by the investigator

19. Regular dose of corticosteroids during the four weeks prior to D1 of this study or
anticipated need of corticosteroids exceeding prednisone 20 mg/day or equivalent, or
any other immunosuppressive therapy within 4 weeks prior to study entry

20. Known infection with human immunodeficiency virus (HIV) or chronic infection with
hepatitis B or hepatitis C virus

21. Pregnant or nursing women, or women of childbearing potential not willing to use an
effective form of contraception during participation in the study and at least three
months thereafter. Male patients not willing to ensure that during the study and at
least three months thereafter no fathering takes place.

Type of Study:


Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Overall frequency of AEs

Outcome Time Frame:

until EoS

Safety Issue:


Principal Investigator

Ralf Bargou, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Medizinische Poliklinik der Julius-Maximilians-Universität Würzburg, Zentrum für Innere Medizin, Oberdürrbacherstr. 6 D-97080 Würzburg


Germany: Paul-Ehrlich-Institut

Study ID:




Start Date:

June 2004

Completion Date:

April 2012

Related Keywords:

  • Non-Hodgkin's Lymphoma, Relapsed
  • Non-Hodgkin's Lymphoma
  • Cancer immunotherapy
  • Monoclonal antibody
  • anti-CD19
  • anti-CD3
  • BiTE
  • Blinatumomab
  • Lymphoma
  • Lymphoma, Non-Hodgkin